Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease
<p dir="ltr">Sickle cell disease (SCD) is a heterogeneous group of inherited disorders characterized by the production of sickle hemoglobin which is less soluble than an adult or fetal hemoglobin. Voxelotor is a hemoglobin S polymerization inhibitor that has been approved for sickle...
Saved in:
| Main Author: | Awni Alshurafa (15468195) (author) |
|---|---|
| Other Authors: | Mohamed A. Yassin (8361183) (author) |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies
by: Mohamed Yassin (4166515)
Published: (2025) -
Knowledge, attitude, and practice of physicians regarding pain management in patients with Sickle cell disease
by: Abdellatif Ismail (14182309)
Published: (2023) -
Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar’s healthcare perspective
by: Ahmad M Adel (21767351)
Published: (2024) -
Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease
by: Asmaa, Al-mansouri
Published: (2023) -
What is Polypharmacy in Patients with Chronic Kidney Disease? A Systematic Review
by: Azhar, Al-Khulaifi
Published: (2023)